CN104055763A - Application of glycine in puerarin injection - Google Patents
Application of glycine in puerarin injection Download PDFInfo
- Publication number
- CN104055763A CN104055763A CN201410248103.XA CN201410248103A CN104055763A CN 104055763 A CN104055763 A CN 104055763A CN 201410248103 A CN201410248103 A CN 201410248103A CN 104055763 A CN104055763 A CN 104055763A
- Authority
- CN
- China
- Prior art keywords
- injection
- puerarin
- glycine
- application
- transfusion
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Landscapes
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Abstract
The invention relates to application of glycine in puerarin injection. According to the injection, the glycine is mixed with the puerarin to be prepared into an injection containing puerarin; or a glycine injection is combined with a puerarin injection for use, so that the adventitious hemolysis untoward effect of the injection containing puerarin is effectively avoided, and thus the safety of administration of the puerarin injection is improved.
Description
Technical field
The present invention relates to the new medical use of glycine, be specifically related to the application in puerarin injection.
Background technology
Glycine (Glycine, Gly) claims again glycine, aminoacetic acid, and molecular formula is C
2h
5nO
2, structural formula NH
2cH
2cOOH, is the simplest neutral amino acid of natural structure, is also one of non essential amino acid intrinsic in body, water-soluble.Application is very extensive, is the important source material of the industries such as medicine, food, chemical industry.In central nervous system, glycine can be combined by the Glycine Receptors on postsynaptic membrane, the effect of performance inhibitory neurotransmitter.Thought, glycine is only synthetic other amino acid whose nitrogenous sources in its hetero-organization in the past.But recent domestic research shows, Gly can obviously lower gene and the protein expression of hepatic tissue LBP mRNA, CD14.Glycine makes cell membrane occur hyperpolarization by the chloride channel activating on liver Kupffer's cells; suppress stream in calcium; reduce intracellular calcium concentration; the cell injury that prevention calcium overload causes; and be proportionate with its concentration within the specific limits, blood plasma transaminase activity is obviously declined, hepatic injury obviously alleviates; liver function is obviously improved, and has significant liver protection.Can also block signal transduction system in mononuclear phagocyte, effectively reduce ETX and monocytic combination rate, and cause the secretion of cytokine TNF-α, IL-6 etc. to reduce, the biological activity of anti-endotoxin, significantly reduce the endotoxic level of blood plasma intestinal source property and (see " progress of colistine sulfate and glycine drug combination " that Liu Mengmeng, Zhao Jie, Gao Cunshuai, Xu Yu, Bi Kedong write, China's animal quarantine, 2012,29 (10): 72-74 page).Aspect myocardial preservation; also find that Gly can alleviate the myocardial ischemic injury that myocardial damage that lipopolysaccharide causes and antagonism induced by pituitrin etc. and (see " impact of glycine on ischemia-reperfusion mouse nitrous oxide system and Bcl-2 mrna expression " that neat good, Lu great Xiang, a Wang Huadong, Qi Renbin, Fu Yongmei, Chen Liping, Li Chujie write; Chinese Journal of Pathophysiology; 2004,20 (1): 42-46 page).At field of medicaments, glycine is except can be used as amino acid transfusion, health product and biochemical reagents, and the independent use of glycine can be treated the nutritional disorder such as myasthenia gravis, iron deficiency anemia disease, with CaCO
3share and can control gastric ulcer, injection glycine calcium acetylsalicylate is the injection antipyretic analgesic of avoiding gastrointestinal reaction, has again anti thrombotic action.Glycine also has sterilization and antisepsis, can suppress bacillus subtilis, escherichia coli.Also can make antioxidant, nutrition fresh-keeping agent, surfactant (seeing " production of glycine and application " that Wu Hua, Chinese are write, fine chemical material and intermediate, 2004,5:22-25 page).
Puerarin is the monomer-isoflavone compounds extracting from the dry root of legume pueraria lobata, 4 ', and 7 one dihydroxy-8-β-D glucone isoflavone.Be widely used in clinically the treatment of cardiovascular disease.Being applied at present the clinical pharmaceutical preparation that contains puerarin is mainly injection.Along with being widely used of puerarin, also more and more about the report of puerarin untoward reaction in recent years, cause the world of medicine's extensive concern.By analyzing nearly 20 years adverse reaction of tcm, puerarin injection ranks the 18th.The untoward reaction of puerarin injection had once been circulated a notice of at national drug adverse reaction monitoring center in the 3rd phase of January in 2003 " adverse drug reaction communication ".Most researchers is thought, puerarin injection be taking 50% propylene glycol as solvent formulated, unavoidably because the difference generation purity of the aspect such as extraction process, technology is inadequate, introduce impurity and cause various reactions (to see " clinical use puerarin injection being occurred to the analysis of untoward reaction " that Xu Xianghui writes, journal of shanghai Chinese medicine, 2006,40 (8): 71-72; " clinical practice of puerarin and the untoward reaction " of writing with Xu Shiguo, time precious traditional Chinese medical science traditional Chinese medicines, 2005,16 (12): 1307-1308).After analyzing, 63 routine puerarin untoward reaction of the domestic main medical journals of Chinese report to 2000-2004 find male 40 examples, female's 23 examples; Year at age 34～81 (57.5 ± 23.5).All cases are intravenous drip administration.Dosage is 0.4～0.6g, and medicine diluent is 5% Glucose Liquid, normal saline, 5% glucose saline etc.The fastest person of reacting generating time is 3min, and the slowest person is 13d, all occurs in administration process.There are responder 47 examples in first administration, responder 16 examples appear in repeat administration.Statistics shows, common adverse reactions has allergy (generate heat, tremble etc., 24 examples), anaphylactic shock (4 example), hemolytic anemia (13 example), hepatic injury, renal damage (7 example), drug fever (10 example), dead (5 example).All cases are all without allergies, and after reaction occurs, drug withdrawal all recovers (except death) through anti symptom treatment.Dosage and used diluent are in package insert prompting range, and institute responds all certainly as due to puerarin.The generation of untoward reaction and suffer from disease independent, have nothing to do with age, sex, contacts without much with drug dilution liquid.Relevant with patient's body constitution difference, particularly elderly and infirm easily occurs.The length of reacting generating time is relevant with the slow degree of Chinese medicine preparation onset (sees flourish " the routine document analysis of puerarin untoward reaction 63 " write whole-heartedly, modern combination of Chinese and Western medicine magazine, 2005,14 (1): 140).Quiet about 10min of puerarin of one patient, appears as acute renal insufficiency, hemolytic anemia (seeing " Puerarin and hemolytic anemia " that Guan Minghua writes, adverse effect magazine, 2003,5:291).Therefore the hemolytic anemia that, puerarin causes is due to puerarin itself.
Summary of the invention
The object of the present invention is to provide the new medical use of glycine, i.e. the application of glycine in puerarin injection, glycine can effectively be prevented and treated the intravascular hemolysis untoward reaction that puerarin brings out.
In fact, the present invention relates to the application of glycine in the time preparing puerarin injection compound preparation, also can with puerarin injection with injection and transfusion the interim fit applications of mode, or with injection and transfusion mode application glycine after then apply again puerarin injection.
For achieving the above object, the technical solution used in the present invention is: glycine is being prepared the new purposes of puerarin injection.Glycine and puerarin injection are with the interim fit applications of mode of injection and transfusion.After the mode application glycine with injection and transfusion, then apply again puerarin injection.
Related content in technique scheme is explained as follows:
1,, in such scheme, described injection, contains following weight portion medicine: 1～50 part of glycine, 1～50000 part of puerarin.
2,, in such scheme, described injection, also contains adjuvant 1～50 weight portion, water for injection 1～10000 weight portion.Described adjuvant is sodium bicarbonate solution, Glucose Liquid, propylene glycol liquid, glucose saline, sodium chloride injection or normal saline.
3,, in such scheme, described injection can be acceptable injection, powder pin or transfusion clinically.
4,, in such scheme, the preparation method of described injection is as described below:
Described powder pin, is made by glycine and puerarin mixing, sterilizing; Or mixed by glycine, puerarin and sodium chloride, be dissolved in water for injection, then adjust pH value to 5.0-8.5 with hydrochloric acid or sodium bicarbonate solution, filter, after filtrate sterilizing, be potted in powdery ampoule sterilizing again and make;
Described injection.Mixed by glycine, puerarin and sodium chloride, be dissolved in water for injection, then adjust pH value 5.0-8.5 with hydrochloric acid or sodium bicarbonate solution, filter, filtrate is potted in sterilizing in ampoule and makes.Or glycine is by 5% Glucose Liquid, 5% glucose saline, propylene glycol liquid (is formed by propylene glycol and normal saline (1: 1) configuration by volume, include propylene glycol 0.5ml/ml), sodium chloride injection or physiological saline solution, mix with puerarin injection, filter, filtrate is potted in sterilizing in ampoule and makes.
Described transfusion, is mixed by glycine, puerarin and sodium chloride, is dissolved in water for injection, then adjusts pH value 5.0-8.5 with hydrochloric acid or sodium bicarbonate solution, dissolves, and filters, and filtrate is potted in sterilizing in saline vial and makes.Or glycine is by 5% Glucose Liquid, 5% glucose saline, propylene glycol liquid (is formed by propylene glycol and normal saline (1: 1) configuration by volume, include propylene glycol 0.5ml/ml), sodium chloride injection or physiological saline solution, mix with puerarin injection, filter, filtrate is potted in sterilizing in ampoule and makes.
5,, in such scheme, described interim fit applications refers in hospital, mixes together transfusion or injection in application puerarin injection with glycine.
6, in such scheme, described then applies puerarin injection after the mode application glycine with injection and transfusion again, refers in hospital, after the mode application glycine of injecting and infuse, then follows the mode application puerarin injection with injection and transfusion.
Puerarin has and has coronary artery dilator and cerebrovascular, reduction myocardial oxygen consumption, improves the effect of microcirculation and antiplatelet aggregation.Clinically for auxiliary treatment coronary heart diseases and angina pectoris, myocardial infarction, retina arteriovenous obstruction, sudden deafness and ischemic cerebrovascular, infantile viral myocarditis, diabetes etc.Puerarin can be made compound puerarin injection for preventing and treating various diseases with glycine compatibility, as for preventing and treating diabetic peripheral neuropathy, hypertension complicated with diabetes mellitus, diabetic nephropathy, acute cerebral infarction, stable angina pectoris, Lower extremity deep venous thrombosis and vertigo due to vertebrobasilar insufficiency etc.But, very easily cause intravascular hemolysis containing the puerarin in puerarin injection.Glycine not only have protect the liver, the multiple physiologically active such as brain-strengthening, present inventor, through studies confirm that glycine also has the intravascular hemolysis untoward reaction that antagonism is brought out by puerarin, improves the safety of puerarin injection administration.
Below in conjunction with the furthermore bright objects of the present invention of some tests and the effect that can reach.
This laboratory reference " technological guidance's principle of Chinese medicine, natural drug zest and hemolytic research " carries out trial test to hemolytic test, find that 8mM puerarin can cause 1% sheep red blood cell (SRBC) haemolysis 10%, external hemolytic test probability of happening is 100%, hemolytic test result is all reappeared, and illustration method can repeat.The method can be used for finding the potential accidental haemolysis of injection, is the feasible test method of carrying out injection new drug development and judge whether to exist sporadic haemolysis, is conducive to reduce the generation of untoward reaction, improves the safety of injection.
Effect and the effect of the injection haemolysis untoward reaction that, glycine antagonism contains puerarin
(1) puerarin injection hemolytic test
Research glycine and puerarin share the impact on sheep red blood cell (SRBC).Get the erythrocyte of the cold sheep of 10 little tails, add respectively glycine and the puerarin of doses, after 10min, observe erythrocytic state and haemolysis incidence rate, analyze experimental result with X2 inspection statistics, seek the antagonism of glycine to the sporadic haemolysis of puerarin injection.Now that report the test is as follows:
1 experiment material
1.1 tested medicines
1., glycine is purchased from Beijing Suo Laibao Science and Technology Ltd. for glycine injection, accurately takes glycine 3mg with electronic balance, is dissolved in normal saline solution, glycine solution is settled to 10mL with 10mL volumetric flask, this be injection 1., concentration is 4mmolL
-1.With microporous filter membrane, (m) filtration sterilization of 0.22 μ, 4 DEG C save backup.
Injection is 2.: 1. injection is diluted to 2mmolL with sterile saline
-1, 10mL, 4 DEG C save backup.
Injection is 3.: 1. injection is diluted to 1mmolL with sterile saline
-1, 10mL, 4 DEG C save backup.
Puerarin injection is 4.: provided by Kang Enbei Zhejiang Pharmaceutical Co, and 2mL, batch number 090501, every mL injection is containing puerarin 50mg.
Puerarin injection (250mM) is 5.: accurately take puerarin powder (purchased from Jiangsu Tian Sheng medicine company limited) 1.041g with electronic balance, with 40% dimethyl sulfoxide (DMSO, DZ0231, AMRESCO) dissolve, ultrasonic dissolution assisting, normal saline solution is diluted to 9mL, and volumetric flask is settled to 10mL, and solution colour is colourless (configuration surroundings: carry out in superclean bench).Solvent is 40%DMSO solution.With microporous filter membrane (m) filtration sterilization of 0.22 μ, 4 DEG C of preservations.
Compound puerarin injection is 6.: get 1. 0.04mL of injection, injection is 0.27mL 4., mix, and 0.31mL altogether, composition injection is 6..Every mL injection is containing puerarin 43.55mg, glycine 38.7 μ g.
Compound puerarin injection is 7.: get 2. 0.04mL of injection, injection is 0.27mL 4., mix, and 0.31mL altogether, composition injection is 7..Every mL injection is containing puerarin 43.55mg, glycine 19.4 μ g.
Compound puerarin injection is 8.: get 3. 0.04mL of injection, injection is 0.27mL 4., mix, and 0.31mL altogether, composition injection is 8..Every mL injection is containing puerarin 43.55mg, glycine 9.68 μ g.
Compound puerarin injection is 9.: get 1. 0.04mL of injection, injection is 0.13mL 5., mix, and 0.17mL altogether, composition injection is 9..Every mL injection is containing puerarin 79.61mg, glycine 70.59 μ g.
Compound puerarin injection is 10.: get 2. 0.04mL of injection, injection is 0.13mL 5., mix, and 0.17mL altogether, composition injection is 10..Every mL injection is containing puerarin 79.61mg, glycine 35.29 μ g.
Compound puerarin injection
: get 3. 0.04mL of injection, injection is 0.13mL 5., mixes 0.17mL altogether, composition injection
.Every mL injection is containing puerarin 79.61mg, glycine 17.65 μ g.
1.2 laboratory animal
Little tail 10 of the sheep (20～30Kg) that tremble with fear, are provided by Xibei Univ. of Agricultural & Forest Science & Technology's zoopery center.15～25 DEG C of room temperatures, under relative humidity 50% condition, raise.
1.3 reagent, instrument
Chloride injection agent, lot number: 31213042402, Shiyao Yinhu Pharmaceutical Co., Ltd. produces; Water for injection, self-control; TGL-16B high speed centrifuge, Hunan Xingke Scientific Instrument Co., Ltd.; HPY-01B biochemical cultivation case, Huangshi Hengfeng Medical Devices Co., Ltd.; BIO-RAD680 microplate reader; Enzyme mark bar is purchased by Haimen, Jiangsu three and Xing Ya medical apparatus and instruments factory and is produced, purchased from Yang Ling Bao Xin equipment company limited of Shaanxi Province.
2 methods
The preparation of 2.1 red blood cell suspensions
10 of the cold sheep of little tail, carry out respectively hemolytic experiment.Every sheep is adopted jugular vein blood 10mL, after heparin sodium (Jiangsu Wanbang Biological Pharmaceutical Co., Ltd.) 160IU anticoagulant, be placed in graduated centrifuge tube, centrifugal 10 minutes with 2000 revs/min, discard blood plasma, add appropriate chloride injection agent washing, centrifugal abandoning supernatant and leukocytic cream.Add again appropriate normal saline shake up, centrifugal, so cyclic washing 3 times, till being water white transparency to centrifugal rear supernatant.Gained packed red cells is become to the red cell suspension of 11% (volume ratio) with normal saline dilution.So far, red cell suspension is ready.
The outer hemolytic experiment design of 2.2 puerarin solution bodies
If puerarin solution effects is 8mM (0.00333gmL in erythrocytic concentration
-1).If negative control group, solvent control group (replacing puerarin solution effects in erythrocyte with DMSO), drug treating group and positive controls.The pH value of measuring puerarin solution with the desk-top pH meter of METTLER TOLEDO is 7.16.
Shown in following table 1, in test tube, add corresponding composition respectively, note application of sample order.Often add after a kind of composition, all shake up gently.After all adding in system etc. all the components in system, light shaking mixes, and places the biochemical cultivation case incubation of 37 DEG C.After 10min, observe haemolysis and aggregation.Aggregation decision method: if having rufous or brownish red flocculent deposit in solution, not disperseing after jolting, show to have red cell agglutination to occur, if can be uniformly dispersed again after condensation product jolting, is pseudoagglutination, is true coagulation if condensation product does not shake loose person.Follow each pipe centrifugal according to 5000rpm/min condition, perusal supernatant fluid color.Get supernatant, detect absorbance value (OD value) in 540nm wavelength place.According to 2005 " technological guidance's principle of Chinese medicine, natural drug zest and hemolytic research ", calculate the hemolysis rate (%) of each group of each pipe by formula:
Hemolysis rate (%)=(drug treating group OD value-negative control group OD value)/(positive control pipe group OD value-negative control group OD value)
Show to have haemolysis to occur with reference to evaluation criterion: hemolysis rate > 5%, and carry out statistical procedures.
The external hemolytic experiment packet design of table 1 puerarin solution and glycine
3 results
This test is investigated in the time of puerarin 8mM concentration, and puerarin injection sporadic hemolytic experiment research 4., is 5. carried out in 40 μ M, 20 μ M, 10 impacts of μ M glycine on 10 sheep red blood cells simultaneously, and experimental result all has itemized record, uses X
2inspection statistics is analyzed, and the results are shown in Table 2.
10 sheep hemolytic test result statistical tables of table 2
Note: compare a P < 0.01 with the negative group of normal saline; With the comparison of puerarin injection group, b P < 0.01
Result shows: haemolysis does not appear in normal saline group, the whole haemolysis of water for injection group: with the comparison of normal saline group, puerarin injection 4., 5. group all occurs that haemolysis, haemolysis incidence rate and normal saline group exist utmost point significant difference (P < 0.01); Hemolytic test result is all reappeared, and illustrates that this hemolytic experiment method is reliable and stable, and result of the test can repeat.With puerarin injection 4., 5. group relatively, compound puerarin injection 6., 7., 8., 9., 10.,
all there is not haemolysis in each group, compound puerarin injection 6., 7., 8., 9., 10.,
each group haemolysis incidence rate all with puerarin injection 4., there is utmost point significant difference (P < 0.01) in group 5.; With the comparison of normal saline group, compound puerarin injection 6., 7., 8., 9., 10.,
each group haemolysis incidence rate all with normal saline group zero difference (P > 0.05); Compound puerarin injection 6., 7., 8., 9., 10.,
it is identical that 4., 5. each group and puerarin injection organize puerarin concentration, is 8mM, but compound puerarin injection 6. and 9., 7. and 10., 8. and
contain respectively 40 μ M, 20 μ M, 10 μ M glycine, and 4., 5. puerarin injection is respectively organized containing glycine.Above results suggest: the application of the glycine of variable concentrations and puerarin compatibility, the haemolysis untoward reaction of all can antagonism being brought out by puerarin, and can make incidence rate be reduced to normal saline level.
Above experimental result shows: puerarin can cause haemolysis, and the injection that contains puerarin all likely causes haemolysis, is adding after glycine, all can eliminate the haemolysis untoward reaction containing puerarin.
Above-mentioned result of the test prompting: the injection that puerarin injection and puerarin and glycine compatibility are made has no the generation of hemolytic reaction.
Therefore, in the time that preparation contains the injection of puerarin or while applying puerarin injection, add glycine, can eliminate the haemolysis untoward reaction that puerarin causes, improved the safety of puerarin injection administration.
Advantage of the present invention is: in the time that preparation contains the injection of puerarin or while applying puerarin injection, adds glycine, there is the intravascular hemolysis untoward reaction that good antagonism is brought out by puerarin, and inexpensive, have no side effect, safety.
Below in conjunction with embodiment, the invention will be further described:
Detailed description of the invention:
The preparation of embodiment 1:(compound puerarin injection)
Get glycine 15mg, puerarin 10g, adds sodium chloride 9g, adds water to 1000mL, adjusts pH to 5.0-8.5 with 1mol/l hydrochloric acid or sodium bicarbonate solution, filter, filtrate be potted in 2,5 or the ampoule of 10mL in, 100 DEG C of sterilizing 30min, obtain injection.This product can be used for auxiliary treatment coronary heart diseases and angina pectoris, myocardial infarction, artery Venous blocks of retina, sudden deafness and ischemic cerebrovascular, infantile viral myocarditis, diabetes etc.This product can intravenous injection or intramuscular injection, each 1～500mL, and 1～3 time on the one 10～20 days is a course for the treatment of, can use continuously 2～3 courses for the treatment of.
The preparation of embodiment 2:(compound puerarin powder pin)
Get glycine 30mg, puerarin 1g, is potted in the powder pin ampoule of 10mL, and 100 DEG C of sterilizing 30min, obtain powder pin.This product can be used for auxiliary treatment coronary heart diseases and angina pectoris, myocardial infarction, artery Venous blocks of retina, sudden deafness and ischemic cerebrovascular, infantile viral myocarditis, diabetes etc.When application, will make powder pin 1～5000mg and sodium chloride injection or normal saline solution and mix, can carry out intravenous injection or intramuscular injection, each 1～500mL, 1～3 time on the one 10～20 days is a course for the treatment of, can use continuously 2～3 courses for the treatment of.
The preparation of embodiment 3:(compound puerarin transfusion)
Get glycine 7.5mg, puerarin 2g, sodium chloride 9g, adds water to 1000mL, adjusts pH to 5.0-8.5 with lmol/l hydrochloric acid or sodium bicarbonate solution, filters, and filtrate is potted in the saline vial of 250ml, and 100 DEG C of sterilizing 30min, are infused.This product can be used for auxiliary treatment coronary heart diseases and angina pectoris, myocardial infarction, artery Venous blocks of retina, sudden deafness and ischemic cerebrovascular, infantile viral myocarditis, diabetes etc.When application, can directly carry out intravenous injection or intramuscular injection, each 1～500mL, 1～3 time on the one 10～20 days is a course for the treatment of, can use continuously 2～3 courses for the treatment of.
Above-described embodiment is only explanation technical conceive of the present invention and feature, and its object is to allow person skilled in the art can understand content of the present invention and implement according to this, can not limit the scope of the invention with this.All equivalences that spirit is done according to the present invention change or modify, within all should being encompassed in protection scope of the present invention.
Claims (8)
1. the application of glycine in puerarin injection.
2. application according to claim 1, it is characterized in that: glycine can be made compound injection application with puerarin injection, also can apply with interim the cooperation simultaneously of mode of injection and transfusion with puerarin injection, or then apply again puerarin injection after the mode application glycine with injection and transfusion.
3. application simultaneously according to claim 2, is characterized in that: puerarin injection and glycine injection mix before for patient's application, then applies in the mode of injection and transfusion.
4. after the mode application glycine with injection and transfusion according to claim 2, then apply again puerarin injection, it is characterized in that: first for after patient applies glycine injection and finish, more then apply puerarin injection.
5. according to the injection described in claim 1,2,3,4 and the application of injection, it is characterized in that: contain following weight portion medicine: 1～50 part of glycine, 1～50000 part of puerarin.
6. according to the injection described in claim 1,2,3,4,5 and the application of injection, it is characterized in that: can contain adjuvant 1～50 weight portion, water for injection 1～10000 weight portion.
7. according to the injection described in claim 1,2,3,4,5,6 and the application of injection, it is characterized in that: described adjuvant can be sodium bicarbonate solution, Glucose Liquid, glucose saline, propylene glycol liquid, sodium chloride injection or normal saline solution.
8. according to the injection described in claim 1,2,3,4,5,6 or 7 and the application of injection, it is characterized in that: described injection and the application of injection can be acceptable injection, powder pin or transfusion clinically.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201410248103.XA CN104055763B (en) | 2014-05-28 | 2014-05-28 | Application of the glycine on the drug for preparing the intravascular hemolysis that prevention puerarin injection induces |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201410248103.XA CN104055763B (en) | 2014-05-28 | 2014-05-28 | Application of the glycine on the drug for preparing the intravascular hemolysis that prevention puerarin injection induces |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN104055763A true CN104055763A (en) | 2014-09-24 |
| CN104055763B CN104055763B (en) | 2018-05-22 |
Family
ID=51543885
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201410248103.XA Expired - Fee Related CN104055763B (en) | 2014-05-28 | 2014-05-28 | Application of the glycine on the drug for preparing the intravascular hemolysis that prevention puerarin injection induces |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN104055763B (en) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN112315950A (en) * | 2020-12-25 | 2021-02-05 | 西北农林科技大学 | Application of phenylalanine in preparing medicine for preventing and treating intravascular hemolysis induced by puerarin injection |
| CN112451481A (en) * | 2020-12-27 | 2021-03-09 | 西北农林科技大学 | Application of gamma globulin in preparing medicine for preventing and treating intravascular hemolysis induced by puerarin injection |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1895263A (en) * | 2006-06-07 | 2007-01-17 | 广州中医药大学 | Use of taurine in preparation of injection containing puerarin |
| EP2295964A1 (en) * | 2009-09-11 | 2011-03-16 | Fresenius Kabi Deutschland GmbH | Irrigation solution |
-
2014
- 2014-05-28 CN CN201410248103.XA patent/CN104055763B/en not_active Expired - Fee Related
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1895263A (en) * | 2006-06-07 | 2007-01-17 | 广州中医药大学 | Use of taurine in preparation of injection containing puerarin |
| EP2295964A1 (en) * | 2009-09-11 | 2011-03-16 | Fresenius Kabi Deutschland GmbH | Irrigation solution |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN112315950A (en) * | 2020-12-25 | 2021-02-05 | 西北农林科技大学 | Application of phenylalanine in preparing medicine for preventing and treating intravascular hemolysis induced by puerarin injection |
| CN112451481A (en) * | 2020-12-27 | 2021-03-09 | 西北农林科技大学 | Application of gamma globulin in preparing medicine for preventing and treating intravascular hemolysis induced by puerarin injection |
| CN112451481B (en) * | 2020-12-27 | 2023-01-13 | 西北农林科技大学 | Application of gamma globulin in preparing medicine for preventing and treating intravascular hemolysis induced by puerarin injection |
Also Published As
| Publication number | Publication date |
|---|---|
| CN104055763B (en) | 2018-05-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN104055763A (en) | Application of glycine in puerarin injection | |
| CN102445500A (en) | Method for detecting macromolecular substances in Yiqifumai injection | |
| CN102138909B (en) | Asparaginase freeze-dried powder injection and preparation method thereof, as well as asparaginase solution | |
| CN100435803C (en) | Use of taurine in preparation of injection containing puerarin | |
| CN102512360B (en) | Torasemide pharmaceutical composition with stabilization and safety for injection | |
| CN104188902B (en) | A kind of production technology of high stability Dalteparin Sodium Injection | |
| CN105640935A (en) | Eribulin mesylate pharmaceutical composition for injection | |
| CN104042603A (en) | Applications of gamma-aminobutyric acid in puerarin injection | |
| CN104042625A (en) | Application of sodium bicarbonate in puerarin injection | |
| CN104042602A (en) | Application of sodium glutamate in puerarin injection | |
| CN103393595B (en) | Pharmaceutical composition of edaravone | |
| CN105287370B (en) | A kind of preparation method of inosine and combinations thereof composition injection | |
| CN108383880A (en) | Target cumarin-platinum (II) complex and its synthetic method and the application of ovarian cancer drug-resistant strain | |
| CN100560068C (en) | The preparation method of Levogyration sulpiride injection and its | |
| CN104606130B (en) | A kind of Tropisetron HCl parenteral solution and preparation method thereof | |
| CN108553413A (en) | Injection esomeprazole sodium | |
| CN103933061A (en) | Application of calcium chloride in puerarin injection | |
| CN104013615A (en) | Application of vitamin C in puerarin injection | |
| CN104013613A (en) | Application of vitamin E in puerarin injection | |
| Hightower et al. | Plasma expander and blood storage effects on capillary perfusion in transfusion after hemorrhage | |
| CN104971040B (en) | A kind of fenoldopam mesylate injection and preparation method thereof | |
| CN100546585C (en) | Compound puerarin injection and preparation method thereof | |
| CN112438971A (en) | Application of methionine in preparing medicine for preventing and treating intravascular hemolysis induced by puerarin injection | |
| CN103961310B (en) | A kind of carbazochrime sodium sulfonate injection and preparation method thereof | |
| CN113476438B (en) | Hypoglycemic composition containing dihydro morin and application thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant | ||
| CF01 | Termination of patent right due to non-payment of annual fee | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20180522 Termination date: 20190528 |